CITIUS PHARMACEUTICALS INC (CTXR)
US17322U2078 - Common Stock
CTXR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While CTXR has a great health rating, there are worries on its profitability. CTXR does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
CTXR had negative earnings in the past year.
In the past year CTXR has reported a negative cash flow from operations.
CTXR had negative earnings in each of the past 5 years.
In the past 5 years CTXR always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -40.96%, CTXR is in line with its industry, outperforming 44.50% of the companies in the same industry.
The Return On Equity of CTXR (-46.41%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -40.96% | ||
| ROE | -46.41% | ||
| ROIC | N/A |
ROA(3y)-26.41%
ROA(5y)-32.34%
ROE(3y)-29.45%
ROE(5y)-39.53%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CTXR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, CTXR has more shares outstanding
CTXR has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CTXR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -2.87, we must say that CTXR is in the distress zone and has some risk of bankruptcy.
CTXR has a Altman-Z score of -2.87. This is comparable to the rest of the industry: CTXR outperforms 41.36% of its industry peers.
There is no outstanding debt for CTXR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.87 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 6.75 indicates that CTXR has no problem at all paying its short term obligations.
The Current ratio of CTXR (6.75) is better than 73.82% of its industry peers.
A Quick Ratio of 6.75 indicates that CTXR has no problem at all paying its short term obligations.
CTXR's Quick ratio of 6.75 is fine compared to the rest of the industry. CTXR outperforms 74.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.75 | ||
| Quick Ratio | 6.75 |
3. Growth
3.1 Past
The earnings per share for CTXR have decreased strongly by -22.13% in the last year.
EPS 1Y (TTM)-22.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2400%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 176.95% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-43.75%
EPS Next 2Y42.52%
EPS Next 3Y65.48%
EPS Next 5Y176.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
CTXR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 509.80, CTXR can be considered very expensive at the moment.
CTXR's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CTXR is cheaper than 71.20% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.83. CTXR is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 509.8 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CTXR's earnings are expected to grow with 65.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.52%
EPS Next 3Y65.48%
5. Dividend
5.1 Amount
No dividends for CTXR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CITIUS PHARMACEUTICALS INC
NASDAQ:CTXR (12/20/2024, 8:04:23 PM)
After market: 2.57 -0.03 (-1.15%)2.6
+0.03 (+1.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners329.06%
Inst Owner Change-22.16%
Ins Owners170.43%
Ins Owner Change0%
Market Cap18.80M
Analysts80
Price Target8.16 (213.85%)
Short Float %N/A
Short Ratio0.12
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.33%
Min EPS beat(2)-17.65%
Max EPS beat(2)18.3%
EPS beat(4)1
Avg EPS beat(4)-109.19%
Min EPS beat(4)-292.16%
Max EPS beat(4)18.3%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)71.43%
PT rev (3m)71.43%
EPS NQ rev (1m)-3650%
EPS NQ rev (3m)-3233.33%
EPS NY rev (1m)-15%
EPS NY rev (3m)-6.98%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 509.8 | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.22 | ||
| P/tB | 1.11 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.89
EYN/A
EPS(NY)0.01
Fwd EY0.2%
FCF(TTM)-4.02
FCFYN/A
OCF(TTM)-4.02
OCFYN/A
SpS0
BVpS11.85
TBVpS2.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -40.96% | ||
| ROE | -46.41% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-26.41%
ROA(5y)-32.34%
ROE(3y)-29.45%
ROE(5y)-39.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.75 | ||
| Quick Ratio | 6.75 | ||
| Altman-Z | -2.87 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2400%
EPS Next Y-43.75%
EPS Next 2Y42.52%
EPS Next 3Y65.48%
EPS Next 5Y176.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-20.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.32%
OCF growth 3YN/A
OCF growth 5YN/A